AstraZeneca (AZN)
NASDAQ: AZN
· Real-Time Price · USD
71.48
1.60 (2.29%)
At close: Jul 01, 2025, 3:59 PM
71.44
-0.06%
After-hours: Jul 01, 2025, 07:50 PM EDT
2.29% (1D)
| Bid | 71.23 |
| Market Cap | 443.27B |
| Revenue (ttm) | 54.98B |
| Net Income (ttm) | 7.77B |
| EPS (ttm) | 2.48 |
| PE Ratio (ttm) | 28.82 |
| Forward PE | 13.7 |
| Analyst | Buy |
| Ask | 71.54 |
| Volume | 6,103,941 |
| Avg. Volume (20D) | 5,316,647 |
| Open | 70.09 |
| Previous Close | 69.88 |
| Day's Range | 70.04 - 72.01 |
| 52-Week Range | 61.24 - 87.68 |
| Beta | 0.17 |
Analyst Forecast
According to 0 analyst ratings, the average rating for AZN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
AstraZeneca is scheduled to release its earnings on Jul 24, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+2.77%
AstraZeneca shares are trading higher after the co...
Unlock content with
Pro Subscription
1 month ago
-2.2%
Shares of pharmaceutical stocks are trading lower. The sector may down on continued weakness amid President Trump's drug pricing executive order.
21 hours ago · proactiveinvestors.co.uk
AstraZeneca shares pop on news CEO wants to move base to USAstraZeneca PLC (LSE:AZN) shares spiked higher on Tuesday afternoon on reports that the boss of the UK pharmaceutical giant wants to move the company to the US. CEO Pascal Soriot wants to the FTSE 100...
23 hours ago · proactiveinvestors.co.uk
AstraZeneca's patent headwinds receding as trial data offers excitementUBS has maintained its 'buy' recommendation on AstraZeneca PLC (LSE:AZN), setting a 12-month price target of 10,121p, reflecting confidence that a wave of late-stage clinical readouts will provide fre...
